Breast Cancer Advocacy Coalition responds to the 'Herceptin or deception' article.

The New Zealand medical journal.

Volumn 119, Issue 1237, 2006, Pages

  Burgess, Elisabeth P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TRASTUZUMAB;

BREAST TUMOR; COST BENEFIT ANALYSIS; DRUG APPROVAL; DRUG CONTROL; DRUG SCREENING; ECONOMICS; FEMALE; HUMAN; METHODOLOGY; NEW ZEALAND; NOTE; PATIENT ADVOCACY; TREATMENT OUTCOME; UNITED KINGDOM;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; DRUG AND NARCOTIC CONTROL; DRUG APPROVAL; DRUG EVALUATION; FEMALE; GREAT BRITAIN; HUMANS; NEW ZEALAND; PATIENT ADVOCACY; TREATMENT OUTCOME;

EID: 33746897363     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Note

References (0)